“These results represent an important de-risking milestone for ongoing commercial development, and are particularly valuable to prospective commercial partners. In addition, they will form the basis for determining the parameters of longer-term repeat dose toxicity testing, which is an essential and important component of Flavocide’s data package in support of global registration and commercialisation of the product.”
We are waiting for the ongoing commercial development and prospective commercial partners to bear fruit soon.
BGT Price at posting:
12.5¢ Sentiment: Buy Disclosure: Held
